76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Amgen Inc
Closed
SectorHealthcare
287.94 1.61
Overview
Share price change
24h
Min
287.17
Max
288.51
Income | 1.1B 1.7B |
|---|---|
Sales | -937M 8.1B |
P/E Sector Avg | 24.741 53.54 |
EPS | 4.9 |
Dividend yield | 3.5 |
Profit margin | 21.23 |
Employees | 28,000 |
EBITDA | -1.7B 1.2B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +12.78% upside |
Dividend yield Sector Avg | 3.50% 2.44% |
|---|---|
Next Earnings | 5 Aug 2025 |
Next Dividend date | 6 Jun 2025 |
Next Ex Dividend date | 15 Aug 2025 |
Market Cap | -12B 146B |
|---|---|
Previous open | 286.33 |
Previous close | 287.94 |
News Sentiment
By Acuity
13%
87%
15 / 381 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Amgen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amgen Inc Forecast
Price Target
By TipRanks
12.78% upside
12 Months Forecast
Average 325 USD 12.78%
High 400 USD
Low 252 USD
Based on 21 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.
Sentiment
By Acuity
15 / 381 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
